Abstract:Post-translational modification of the p53 signaling pathway plays an important role in cell cycle progression and stress-induced apoptosis. Indeed, a large body of work has shown that dysregulation of p53 and its E3 ligase MDM2 by the ubiquitin-proteasome system (UPS) promotes carcinogenesis and malignant transformation. Thus, drug discovery efforts have focused on the restoration of wild-type p53 activity or inactivation of oncogenic mutant p53 by targeted inhibition of UPS components, particularly key deubiquitinases (DUBs) of the ubiquitin-specific protease (USP) class. However, development of selective small-molecule USP inhibitors has been challenging, partly due to the highly conserved structural features of the catalytic sites across the class. To tackle this problem, we devised a protein engineering strategy for rational design of inhibitors for DUBs and other UPS proteins. We employed a phage-displayed ubiquitin variant (UbV) library to develop inhibitors targeting the DUBs USP7 and USP10, which are involved in regulating levels of p53 and MDM2. We were able to identify UbVs that bound USP7 or USP10 with high affinity and inhibited deubiquitination activity. We solved the crystal structure of UbV.7.2 and rationalized the molecular basis for enhanced affinity and specificity for USP7. Finally, cell death was increased significantly by UbV.7.2 expression in a colon cancer cell line that was treated with the chemotherapy drug cisplatin, demonstrating the therapeutic potential of inhibiting USP7 by this approach.

Supplementary Figures 1 Through 6 from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Supplementary Methods from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Supplementary Figure Legend from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Inhibition of USP1 Induces Apoptosis Via ID1/AKT Pathway in B-cell Acute Lymphoblastic Leukemia Cells

Inhibition of USP1 Reverses the Chemotherapy Resistance Through Destabilization of MAX in the Relapsed/refractory B-cell Lymphoma

Supplementary Figure 1 from Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and is a Potent Inhibitor of Pancreatic Cancer Cell Survival

Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47

Inhibition of the Deubiquitinase USP10 Induces Degradation of SYK

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3-d]pyrimidin-7(8H)-one Derivatives As Potent USP1 Inhibitors

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Inhibition of USP10 Induces Degradation of Oncogenic FLT3.

Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5

USP7 inhibition inhibits proliferation and induces megakaryocytic differentiation in MDS cells by upregulating gelsolin

Structural and biochemical insights on the mechanism of action of the clinical USP1 inhibitor, KSQ-4279

Targeting USP47 Overcomes Tyrosine Kinase Inhibitor Resistance and Eradicates Leukemia Stem/progenitor Cells in Chronic Myelogenous Leukemia

Suppression of USP7 Induces BCR-ABL Degradation and Chronic Myelogenous Leukemia Cell Apoptosis

Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.